444 related articles for article (PubMed ID: 8931409)
1. Effects of ursodeoxycholic acid on hepatic inflammation and histological stage in patients with primary biliary cirrhosis.
Batts KP; Jorgensen RA; Dickson ER; Lindor KD
Am J Gastroenterol; 1996 Nov; 91(11):2314-7. PubMed ID: 8931409
[TBL] [Abstract][Full Text] [Related]
2. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis.
Angulo P; Batts KP; Therneau TM; Jorgensen RA; Dickson ER; Lindor KD
Hepatology; 1999 Mar; 29(3):644-7. PubMed ID: 10051462
[TBL] [Abstract][Full Text] [Related]
3. Relationship between biliary and serum bile acids and response to ursodeoxycholic acid in patients with primary biliary cirrhosis.
Lindor KD; Lacerda MA; Jorgensen RA; DeSotel CK; Batta AK; Salen G; Dickson ER; Rossi SS; Hofmann AF
Am J Gastroenterol; 1998 Sep; 93(9):1498-504. PubMed ID: 9732932
[TBL] [Abstract][Full Text] [Related]
4. Effect of pretransplantation ursodeoxycholic acid therapy on the outcome of liver transplantation in patients with primary biliary cirrhosis.
Heathcote EJ; Stone J; Cauch-Dudek K; Poupon R; Chazouilleres O; Lindor KD; Petz J; Dickson ER; Poupon RE
Liver Transpl Surg; 1999 Jul; 5(4):269-74. PubMed ID: 10388499
[TBL] [Abstract][Full Text] [Related]
5. Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA-treated patients with primary biliary cirrhosis.
Corpechot C; Poujol-Robert A; Wendum D; Galotte M; Chrétien Y; Poupon RE; Poupon R
Liver Int; 2004 Jun; 24(3):187-93. PubMed ID: 15189267
[TBL] [Abstract][Full Text] [Related]
6. Results of long-term ursodiol treatment for patients with primary biliary cirrhosis.
Jorgensen R; Angulo P; Dickson ER; Lindor KD
Am J Gastroenterol; 2002 Oct; 97(10):2647-50. PubMed ID: 12385454
[TBL] [Abstract][Full Text] [Related]
7. Prognosis of ursodeoxycholic Acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients.
ter Borg PC; Schalm SW; Hansen BE; van Buuren HR;
Am J Gastroenterol; 2006 Sep; 101(9):2044-50. PubMed ID: 16848809
[TBL] [Abstract][Full Text] [Related]
8. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials.
Shi J; Wu C; Lin Y; Chen YX; Zhu L; Xie WF
Am J Gastroenterol; 2006 Jul; 101(7):1529-38. PubMed ID: 16863557
[TBL] [Abstract][Full Text] [Related]
9. Improvement of biliary enzyme levels and itching as a result of long-term administration of ursodeoxycholic acid in primary biliary cirrhosis.
Matsuzaki Y; Tanaka N; Osuga T; Aikawa T; Shoda J; Doi M; Nakano M
Am J Gastroenterol; 1990 Jan; 85(1):15-23. PubMed ID: 1967512
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis.
Bonnand AM; Heathcote EJ; Lindor KD; Poupon RE
Hepatology; 1999 Jan; 29(1):39-43. PubMed ID: 9862847
[TBL] [Abstract][Full Text] [Related]
11. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid.
Kuiper EM; Hansen BE; de Vries RA; den Ouden-Muller JW; van Ditzhuijsen TJ; Haagsma EB; Houben MH; Witteman BJ; van Erpecum KJ; van Buuren HR;
Gastroenterology; 2009 Apr; 136(4):1281-7. PubMed ID: 19208346
[TBL] [Abstract][Full Text] [Related]
12. A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis. UDCA-PBC Study Group.
Poupon RE; Huet PM; Poupon R; Bonnand AM; Nhieu JT; Zafrani ES
Hepatology; 1996 Nov; 24(5):1098-103. PubMed ID: 8903382
[TBL] [Abstract][Full Text] [Related]
13. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial.
Rautiainen H; Kärkkäinen P; Karvonen AL; Nurmi H; Pikkarainen P; Nuutinen H; Färkkilä M
Hepatology; 2005 Apr; 41(4):747-52. PubMed ID: 15754377
[TBL] [Abstract][Full Text] [Related]
14. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group.
Poupon RE; Balkau B; Eschwège E; Poupon R
N Engl J Med; 1991 May; 324(22):1548-54. PubMed ID: 1674105
[TBL] [Abstract][Full Text] [Related]
15. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation.
Charatcharoenwitthaya P; Pimentel S; Talwalkar JA; Enders FT; Lindor KD; Krom RA; Wiesner RH
Liver Transpl; 2007 Sep; 13(9):1236-45. PubMed ID: 17763401
[TBL] [Abstract][Full Text] [Related]
16. The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis.
Heathcote EJ; Cauch-Dudek K; Walker V; Bailey RJ; Blendis LM; Ghent CN; Michieletti P; Minuk GY; Pappas SC; Scully LJ
Hepatology; 1994 May; 19(5):1149-56. PubMed ID: 8175136
[TBL] [Abstract][Full Text] [Related]
17. Long-term ursodeoxycholic acid therapy for primary biliary cirrhosis: a follow-up to 12 years.
Chan CW; Gunsar F; Feudjo M; Rigamonti C; Vlachogiannakos J; Carpenter JR; Burroughs AK
Aliment Pharmacol Ther; 2005 Feb; 21(3):217-26. PubMed ID: 15691295
[TBL] [Abstract][Full Text] [Related]
18. Gene expression profiling of early primary biliary cirrhosis: possible insights into the mechanism of action of ursodeoxycholic acid.
Chen L; Borozan I; Milkiewicz P; Sun J; Meng X; Coltescu C; Edwards AM; Ostrowski MA; Guindi M; Heathcote EJ; McGilvray ID
Liver Int; 2008 Aug; 28(7):997-1010. PubMed ID: 18422935
[TBL] [Abstract][Full Text] [Related]
19. Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group.
Poupon RE; Bonnand AM; Chrétien Y; Poupon R
Hepatology; 1999 Jun; 29(6):1668-71. PubMed ID: 10347106
[TBL] [Abstract][Full Text] [Related]
20. Clinical and biochemical features and therapy responses in primary biliary cirrhosis and primary biliary cirrhosis-autoimmune hepatitis overlap syndrome.
Günsar F; Akarca US; Ersöz G; Karasu Z; Yüce G; Batur Y
Hepatogastroenterology; 2002; 49(47):1195-200. PubMed ID: 12239904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
